Treatment of Insufficient Superficial and Perforatring Veins of the Lower Limb Using HIFU
NCT ID: NCT04280679
Last Updated: 2020-10-06
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
22 participants
INTERVENTIONAL
2020-03-03
2020-09-10
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
The original Sonovein device was tested in a clinical trial in 50 subjects and received CE Mark. That device has been updated yielding the current version of Sonovein 2. Based on the technical similarities between both devices in term of design, performance and principle of operation, the clinical data for Sonovein is sufficient to assure conformity of the Sonovein 2 with the respected essential requirements. At the same time, the compagny wishes to pursue the standardisation of the clinical practice with the second generation device and is, therefore, conducting this limited trial in 20 evaluable cases (from the planned 22 patients to be included). A "case" is defined as procedure conducted on a distinct vein.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Treatment of Insufficient Superficial and Perforating Veins of the Lower Limb Using HIFU
NCT03304834
Safety of the Sonablate HIFU System for the Ablation of Incompetent Veins of the Periphery
NCT06642051
Extracorporeal Flow Abolition in Relation With Primary Insufficiency of Great Saphenous Veins (GSV) Using High Intensity Focused Ultrasound (HIFU) Generated by Sonovein: A Multi Center Prospective Pivotal Study
NCT05926830
Minimally Invasive Treatment of Primary Great Saphenous Vein (GSV) Insufficiency Using High Intensity Focused Ultrasound (HIFU)
NCT05193643
RCT Comparing Standard Cannula Delivered FS, UGFS and ClariVein® in the Management of SVI
NCT02010437
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Arm of patient treated by HIFU
Compression bandages
Sonovein 2
Patient are treated with the HIFU device and the pysician is doing a compressive bandage
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Sonovein 2
Patient are treated with the HIFU device and the pysician is doing a compressive bandage
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. Physical condition allowing ambulation after the procedure
3. Availability of the patient for all the follow-up visits
4. Targeted tissue reachable for treatment with the device-meaning between 5mm and 26mm below the skin surface
5. Age over 18 years of age at the time of enrollment
6. No acute venous thrombosis
7. No complete, or near complete deep vein thrombosis
8. Patient has signed a written informed consent
9. Targeted structure sonographically visible
Exclusion Criteria
2. Known allergic reaction to anesthetic to be used
3. Legally incapacitated or imprisoned patients
4. Patient's vein target not clearly visible on the ultrasound images (B mode) at the inclusion visit
5. Patient participating in another clinical trial involving an investigational drug, device or biologic
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Theraclion
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Alfred OBERMAYER, MD
Role: PRINCIPAL_INVESTIGATOR
Karl Landsteiner Insitut fur funktionelle Phlebochirurgie
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Karl Landsteiner Institut für funktionelle Phlebochirurgie
Melk, , Austria
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
HIFU-VN-002
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.